Theranos

Everlaw Summit Draws World-Class Ediscovery Experts and Practitioners for 3 Days of Legal Education and Networking in San Francisco, Nov. 2 to 4, 2022

Retrieved on: 
Tuesday, September 13, 2022

OAKLAND, Calif., Sept. 13, 2022 /PRNewswire/ -- Everlaw, the cloud-native investigation and litigation platform, will host Everlaw Summit, the company's flagship in-person experience for its customers, partners and the greater ediscovery community from Nov. 2 to 4, 2022 at the Palace Hotel in San Francisco. The event will feature live programming centering on education, connection and transformation with 26 sessions and six networking events, including Women in Ediscovery, as well as the Everlaw Summit Awards.

Key Points: 
  • The event will feature live programming centering on education, connection and transformation with 26 sessions and six networking events, including Women in Ediscovery, as well as the Everlaw Summit Awards.
  • "We designed Summit to deliver a high return-on-investment for legal practitioners' valuable time," said Everlaw Founder and CEO AJ Shankar.
  • "We're bringing together the best in the legal industry for three days of insights and collaboration, united around the goal of uncovering the truth faster."
  • The Everlaw Summit Awards recognizes individuals, organizations and law firms who are making significant impact, innovation and contributions across the legal and ediscovery sector.

BIOMEDevice Boston Brings Back "Master Class Start-Up Series" in Partnership with MassMEDIC

Retrieved on: 
Friday, August 12, 2022

The pandemic fueled the introduction of new medtech and digital health start-ups, which brought significant investment from venture funds.

Key Points: 
  • The pandemic fueled the introduction of new medtech and digital health start-ups, which brought significant investment from venture funds.
  • MassMEDIC brings its unparalleled expertise and experience to educating, connecting, creating awareness and advocating for the medical device ecosystem to this program.
  • In addition to the Master Class Start-Up Series, BIOMEDevice Boston offers world-class conference content led by renowned industry experts.
  • Follow BIOMEDevice Boston for the full conference agenda and speaker lineup.

Theranos Whistleblower, Segway Inventor, and MedExecWomen to Keynote BIOMEDevice Boston 2022

Retrieved on: 
Wednesday, July 27, 2022

Theranos whistleblower Erika Cheung, Segway inventor and co-founder Dean Kamen, and a panel of senior-level executives from MedExecWomen are confirmed to keynote the 2022 edition of BIOMEDevice Boston .

Key Points: 
  • Theranos whistleblower Erika Cheung, Segway inventor and co-founder Dean Kamen, and a panel of senior-level executives from MedExecWomen are confirmed to keynote the 2022 edition of BIOMEDevice Boston .
  • We are thrilled to have Erika, Dean, and the MedExecWomen panel presenting at BIOMEDevice Boston, said Adrienne Zepeda, Group Event Director, BIOMEDevice Boston.
  • Biotech Week Boston 2022 will take place from September 27-30 at the Boston Convention & Exhibition Center.
  • Follow BIOMEDevice Boston on social and join the conversation #BIOMEDevice:

Theranos Whistleblowers Erika Cheung and Tyler Shultz to Speak at the 2022 AACC Annual Scientific Meeting

Retrieved on: 
Wednesday, June 29, 2022

WASHINGTON, June 29, 2022 /PRNewswire/ -- AACC is pleased to announce that Erika Cheung and Tyler Shultztwo of the key whistleblowers who helped bring down Theranoswill speak in a special fireside chat at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago.

Key Points: 
  • WASHINGTON, June 29, 2022 /PRNewswire/ -- AACC is pleased to announce that Erika Cheung and Tyler Shultztwo of the key whistleblowers who helped bring down Theranoswill speak in a special fireside chat at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago.
  • However, when laboratory experts were finally able to evaluate Theranos' actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology's capabilities.
  • Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting.
  • "It is a great honor to be able to feature Erika Cheung and Tyler Shultz at the AACC Annual Scientific Meeting," said Master.

MIMEDX Comments on Prescience Point’s False and Misleading Statements

Retrieved on: 
Monday, May 9, 2022

MARIETTA, Ga., May 09, 2022 (GLOBE NEWSWIRE) -- MIMEDX Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today commented on Prescience Point Capital Management’s (“Prescience Point”) highly misleading press release on May 6, 2022. MIMEDX urges shareholders to vote “FOR” the Company’s highly qualified and independent directors – Dr. Phyllis Gardner and James L. Bierman – on the WHITE proxy card.

Key Points: 
  • A companys integrity and credibility stem from exemplary leadership, and MIMEDX does not compromise on its core values and commitments.
  • Both are highly respected in the life sciences industry and have made significant contributions to our successful turnaround, positioning MIMEDX for substantial shareholder value creation.
  • Mr. Asbahis commentary only reinforces the Boards belief that Prescience Points interests are short-term and not aligned with those of all shareholders.
  • While Prescience Point attempts to distract shareholders with misleading facts and statements, their public comments betray their true motivation Mr. Asbahi and Prescience Point explicitly stated their interest in a sale of AMNIOFIX or the entire business later this year.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nano-X Imaging Ltd. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 14, 2020

Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On September 15, 2020, Citron Research (Citron) published the report entitled, Nano-X Imaging (NNOX) A Complete Farce on the Market Theranos 2.0 (the Citron Report).
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Nano-X Imaging Ltd. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, November 12, 2020

Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On September 15, 2020, Citron Research (Citron) published the report entitled, Nano-X Imaging (NNOX) A Complete Farce on the Market Theranos 2.0 (the Citron Report).
  • When the true details entered the market, the lawsuit claims that investors suffered damages.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

NNOX 7-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Alert Nano-X Imaging (NNOX) Investors to November 16th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact the Firm

Retrieved on: 
Monday, November 9, 2020

Citron also alleged that Nano-Xs commercial agreements appear to be no more than fake customers.

Key Points: 
  • Citron also alleged that Nano-Xs commercial agreements appear to be no more than fake customers.
  • Then, on Sept. 17, 2020 Empire Financial Research issued a report, stating that Nano-X looks like Theranos 2.0 and that this stock is worthless.
  • If you are a Nano-X investor or may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nano-X Imaging Ltd. of Class Action Lawsuit and Upcoming Deadline – NNOX

Retrieved on: 
Tuesday, October 27, 2020

If you are a shareholder who purchased Nano-X securities during the class period, you have until November 16, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.

Key Points: 
  • If you are a shareholder who purchased Nano-X securities during the class period, you have until November 16, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • On September 15, 2020, Citron Research published a report titled Nano-X Imaging (NNOX) A Complete Farce on the Market Theranos 2.0 (the Citron Report).
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nano-X Imaging Ltd. of Class Action Lawsuit and Upcoming Deadline –  NNOX

Retrieved on: 
Wednesday, October 21, 2020

If you are a shareholder who purchased Nano-X securities during the class period, you have until November 16, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.

Key Points: 
  • If you are a shareholder who purchased Nano-X securities during the class period, you have until November 16, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • On September 15, 2020, Citron Research published a report titled Nano-X Imaging (NNOX) A Complete Farce on the Market Theranos 2.0 (the Citron Report).
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.